{"nctId":"NCT01064414","briefTitle":"An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment","startDateStruct":{"date":"2010-06"},"conditions":["Diabetes Mellitus, Type 2","Renal Insufficiency"],"count":272,"armGroups":[{"label":"Canagliflozin 100 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canagliflozin"]},{"label":"Canagliflozin 300 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canagliflozin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Canagliflozin","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with T2DM not on an AHA or on any AHA in monotherapy or combination therapy (including oral or non oral agents)\n* Patients with reduced kidney function\n\nExclusion Criteria:\n\n* History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy\n* Have proliferative diabetic retinopathy for which treatment is planned during the course of the study\n* Kidney disease that required treatment with immunosuppressive therapy, history of dialysis or kidney transplant, presence of nephrotic syndrome (eg, severe proteinuria with hypoalbuminemia and/or edema), or inflammatory kidney disease\n* Receiving anti hypertensive or anti-hyperlipidemic therapy not on a stable regimen\n* History of a severe hypoglycemic episode within 6 months before screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"25 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.090"},{"groupId":"OG001","value":"-0.33","spread":"0.090"},{"groupId":"OG002","value":"-0.44","spread":"0.089"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c <7% at Week 26","description":"The table below shows the percentage of patients with HbA1c \\<7% at Week 26 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.2","spread":null},{"groupId":"OG001","value":"27.3","spread":null},{"groupId":"OG002","value":"32.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.49","spread":"5.089"},{"groupId":"OG001","value":"-14.9","spread":"5.089"},{"groupId":"OG002","value":"-11.7","spread":"5.099"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":90},"commonTop":["Hypoglycaemia","Nasopharyngitis","Urinary tract infection","Diarrhoea","Oedema peripheral"]}}}